My other irritation with the last conference call(and prior one) is that the questioners--seem to know the petition to change the SPA and the why's behind it--prior to it being disclosed to the average Joe shareholder. I don't follow a lot of biotech's anymore, but my experience with SRPT was similar in that the analysts were always two steps ahead of the the retail shareholders(although that experience ended quite well for me so I shouldn't really complain too much=)
I also have a special plan that I won't disclose regarding VBLT next year which I will disclose in do course to maximize my potential gains. LOL.
Regarding the drop out rate. The CEO did say that the drop out rate is "very low" on the last conference call.
On the recruiting success, he also said that he is guessing and his guess is that there is high demand for VB-111 due to its success in the prior phase.
The company is blinded to the data so only the investigators know what is really going on ... and they're not talking.
News 
Market Data 
Discover 
